Evidence map›Paper›PMID 40250719›Full record

ArticleNeurobiology of disease2025

Early α-synuclein aggregation decreases corticostriatal glutamate drive and synapse density.

Charlotte F Brzozowski, Harshita Challa, Nolwazi Z Gcwensa, Dominic Hall, Douglas Nabert, Nicole Chambers, Ignacio Gallardo, Michael Millet, Laura Volpicelli-Daley, Mark S Moehle

Abstract read
In one paragraph

Article in Neurobiology of disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Review
  6. Article
  7. Review
  8. Review
  9. Article
  10. Review
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Charlotte F BrzozowskiDepartment of Neurology, Killon Center for Neurodegeneration and Experimental Therapeutics, University of Alabama at Birmingham, Birmingham, AL 35294, USA; Department of Pharmacology and Therapeutics, Center for Translational Research in Neurodegeneration, and Fixel Institute, University of Florida, Gainesville, FL 32610, USA.
Harshita ChallaDepartment of Neurology, Killon Center for Neurodegeneration and Experimental Therapeutics, University of Alabama at Birmingham, Birmingham, AL 35294, USA.
Nolwazi Z GcwensaDepartment of Neurology, Killon Center for Neurodegeneration and Experimental Therapeutics, University of Alabama at Birmingham, Birmingham, AL 35294, USA.
Dominic HallDepartment of Pharmacology and Therapeutics, Center for Translational Research in Neurodegeneration, and Fixel Institute, University of Florida, Gainesville, FL 32610, USA.
Douglas NabertDepartment of Pharmacology and Therapeutics, Center for Translational Research in Neurodegeneration, and Fixel Institute, University of Florida, Gainesville, FL 32610, USA.
Nicole ChambersDepartment of Pharmacology and Therapeutics, Center for Translational Research in Neurodegeneration, and Fixel Institute, University of Florida, Gainesville, FL 32610, USA.
Ignacio GallardoDepartment of Pharmacology and Therapeutics, Center for Translational Research in Neurodegeneration, and Fixel Institute, University of Florida, Gainesville, FL 32610, USA.
Michael MilletDepartment of Pharmacology and Therapeutics, Center for Translational Research in Neurodegeneration, and Fixel Institute, University of Florida, Gainesville, FL 32610, USA.
Laura Volpicelli-DaleyDepartment of Neurology, Killon Center for Neurodegeneration and Experimental Therapeutics, University of Alabama at Birmingham, Birmingham, AL 35294, USA.
Mark S MoehleDepartment of Pharmacology and Therapeutics, Center for Translational Research in Neurodegeneration, and Fixel Institute, University of Florida, Gainesville, FL 32610, USA. Electronic address: mark.moehle@ufl.edu.

Funding

Role of GlcSph in cognitive deficits in Lewy body dementiasR01AG081433 · NIA · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI Laura A. Volpicelli-Daley · 2023 to 2026
$2.5M
Supplement to Promote Diversity in Health-Related ResearchR01NS132293 · NINDS · UNIVERSITY OF FLORIDA · PI Mark S Moehle · 2023 to 2026
$2.2M
M4 muscarinic acetylcholine receptor signaling as a potent regulator of motor deficitsR00NS110878 · NINDS · UNIVERSITY OF FLORIDA · PI MOEHLE, MARK S · 2021 to 2023
$742k
NIA NIH HHS R01 AG081433NINDS NIH HHS R00 NS110878NINDS NIH HHS R01 NS132293
6 · The paper itself

Abstract

Neuronal inclusions of α-synuclein (α-syn) are pathological hallmarks of Parkinson's disease (PD) and Dementia with Lewy Bodies (DLB). α-Syn pathology accumulates in cortical neurons which project to the striatum. To understand how α-syn pathology affects cortico-striatal synapses at early time points before significant dopamine neuron loss, pre-formed α-syn fibrils (PFF) were injected into the striatum to induce endogenous α-syn aggregation in corticostriatal-projecting neurons. Electrophysiological recordings of striatal spiny projection neurons (SPNs) from acute slices found a significant decrease in evoked corticostriatal glutamate release and corticostriatal synaptic release sites in mice with PFF-induced aggregates compared to monomer injected mice. Expansion microscopy, confocal microscopy and Imaris reconstructions were used to identify VGLUT1 positive presynaptic terminals juxtaposed to Homer1 positive postsynaptic densities, termed synaptic loci. Quantitation of synaptic loci density revealed an early loss of corticostriatal synapses. Immunoblots of the striatum showed reductions in expression of pre-synaptic proteins VGLUT1, VAMP2 and Snap25, in mice with α-syn aggregates compared to controls. Paradoxically, a small percentage of remaining VGLUT1+ synaptic loci positive for pS129-α-syn aggregates showed enlarged volumes compared to nearby synapses without α-syn aggregates. Our combined physiology and high-resolution imaging data point to an early loss of corticostriatal synapses in mice harboring α-synuclein inclusions, which may contribute to impaired basal ganglia circuitry in PD and DLB.

Indexed as

alpha-SynucleinCerebral CortexCorpus StriatumGlutamic AcidProtein Aggregation, PathologicalSynapsesAnimalsMaleMiceMice, Inbred C57BLVesicular Glutamate Transport Protein 1alpha-SynucleinGlutamic AcidVesicular Glutamate Transport Protein 1Dementia with Lewy bodiesGlutamatergicParkinson's diseaseStriatumSynapsesΑ-Synuclein

Identifiers

PMID40250719
PMCPMC12959963

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.